We evaluated the long-term effect of early angiotensin-converting enzyme (ACE) inhibition (enalapril maleate) as monotherapy to postpone or prevent congestive heart failure (CHF) in asymptomatic dogs with mitral regurgitation (MR) attributable to myxomatous valvular disease (MVD) in a prospective, randomized, double-blinded, placebo-controlled multicenter trial involving 14 centers in Scandinavia. Two hundred twenty-nine Cavalier King Charles (CKC) Spaniels with MR attributable to MVD but no signs of CHF were randomly allocated to treatment with enalapril 0.25-0.5 mg daily (n 116) or to placebo groups (n 113). Each dog was evaluated by physical examination, electrocardiography, and thoracic radiography at entry and every 12 months (30 days). The number of dogs developing heart failure was similar in the treatment and placebo groups (n 50 [43%] and n 48 [42%], respectively; P .99). The estimated means, adjusted for censored observations, for the period from initiation of therapy to heart failure were 1,150 50 days for dogs in the treatment group and 1,130 50 days for dogs in the placebo group (P .85). When absence or presence of cardiomegaly at the entrance of the trial was considered, there were still no differences between the treatment and placebo groups (P .98 and .51, respectively). Multivariate analysis showed that enalapril had no significant effect on the time from initiation of therapy to heart failure (P .86). Long-term treatment with enalapril in asymptomatic dogs with MVD and MR did not delay the onset of heart failure regardless of whether or not cardiomegaly was present at initiation of the study.

The aim of this study was to investigate effects of dietary levels of histidine (His) and iron (Fe) on cataract development in two strains of Atlantic salmon monitored through parr-smolt transformation. Three experimental diets were fed: (i) a control diet (CD) with 110 mg kg )1 Fe and 11.7 g kg )1 His; (ii) CD supplemented with crystalline His to a level of 18 g kg )1 (HD); and (iii) HD with added iron up to 220 mg kg )1 (HID). A cross-over design, with two feeding periods was used. A 6-week freshwater (FW) period was followed by a 20-week period, of which the first three were in FW and the following 17 weeks in sea water (SW). Fish were sampled for weighing, cataract assessment and tissue analysis at five time points. Cataracts developed in all groups in SW, but scores were lower in those fed high His diets (P < 0.05). This effect was most pronounced when HD or HID was given in SW, but was also observed when these diets were given in FW only. Histidine supplementation had a positive effect on growth performance and feed conversion ratio (P < 0.05), whereas this did not occur when iron was added. Groups fed HD or HID had higher lens levels of His and N-acetyl histidine (NAH), the latter showing a marked increase post-smoltification (P < 0.05). The HD or HID groups also showed higher muscle concentrations of the His dipeptide anserine (P < 0.05). There was a strong genetic influence on cataract development in the CD groups (P < 0.001), not associated with tissue levels of His or NAH. The role of His and Hisrelated compounds in cataractogenesis is discussed in relation to tissue buffering, osmoregulation and antioxidation.

This study demonstrates the positive association between PLD and glaucoma, between narrowing of the iridocorneal angle and glaucoma and the effect of age on the iridocorneal angle. Mating of dogs with normal iridocorneal angles appears to reduce the presence and degree of abnormal appearance of the iridocorneal angle in the offspring. However, breeding only dogs with normal iridocorneal angles without consideration of their relationship to dogs with glaucoma is not a guarantee for preventing glaucoma in the offspring.

No abstract

In the period from winter 1996 to autumn 1999, three feeding trials were conducted to study the possible role of mammalian blood meal in preventing lens opacities in Atlantic salmon. In addition to blood meal supplemented feed, experimental diets were formulated, aiming to mimic the total concentrations of selected elements present in blood meal (BM) enriched diets; the amino acid histidine (His) and the mineral iron (Fe). In addition, these diets were supplemented with Zn. The trials included different rearing conditions, sizes and strains of Atlantic salmon; one small scale feeding experiment with presmolt of Strain A in fresh water (Trial 1) and two semi large trials with sub-yearling (S0s) and yearling (S1s) smolts of Strains A and B in seawater (Trials 2 and 3). The trials included duplicate or triplicate feeding groups and lasted 6-12 months. Standard commercial diets not supplemented with BM were used as controls. High prevalence of cataract developed over time in all three studies, with end point ranges as follows; Trial 1: 40-52 %; Trial 2: 51-83 %; Trial 3: 63-100%. The cataracts normally first appeared in the anterior and/or posterior cortical region and later affected the perinuclear region. In all the experiments, there was a significant cataract preventative effect of both the BM supplemented and experimental diets compared to the respective control diets. To some extent, cataract incidence was reduced, but primarily cataractogenesis was less severe in these groups. A concurrent positive effect on growth of both added BM and experimental diets was observed in the two seawater trials, probably related to maintaining vision and feed uptake ability. In one of the trials, there were significant differences in cataract susceptibility between the two strains, measured both as frequency and severity of cataractous changes. Our data suggest that elevated concentrations of dietary His and/or Fe mitigate cataract formation. KEY WORDS